

*Accepted as poster #166 at the European Workshop for Rheumatology Research (EWRR) 2020, Leuven, Belgium, February 13–15, 2020*

## **Loxecivint (SM04690), a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Demonstrated Cartilage-Protective Effects on Human Osteoarthritic Explants**

Vishal Deshmukh, PhD<sup>1</sup>, Shawn Grogan, PhD<sup>2</sup>, Timothy Seo, MS<sup>1</sup>, Deepti Bhat, MS<sup>1</sup>, William Bugbee, MD<sup>2</sup>, Darryl D’Lima, MD, PhD<sup>2</sup>, Yusuf Yazici, MD<sup>1</sup>

<sup>1</sup>Samumed, LLC, San Diego, CA

<sup>2</sup>Shiley Center for Orthopaedic Research and Education at Scripps Clinic, San Diego, CA

**Background:** Wnt pathway upregulation contributes to knee osteoarthritis (OA) through osteocyte differentiation, cartilage thinning, and inflammation. Lorcivint (LOR; SM04690), a novel, small-molecule CLK/DRYK1A inhibitor, demonstrated disease-modifying potential for knee OA via Wnt pathway modulation in preclinical studies. Further studies were performed to evaluate cartilage-protective effects of LOR on human OA explants from total knee replacement (TKR) donors.

**Methods:** Knee joint tissue from 22 TKR donors was obtained. IRB approval was obtained from Scripps Health. Cartilage was scored using the Outerbridge classification system based on gross appearance (grade 1=least-damaged tissue, grade 4=most-damaged tissue). Cartilage explants (4 mm in diameter) with Outerbridge grades 2–3 were harvested and cultured for 48 hours to reach metabolic stability. These were treated with LOR (10 nM, 30 nM) or DMSO and stimulated with either IL-1 $\beta$  (10 ng/ml) or TNF- $\alpha$  (20 ng/ml)+oncostatin M (OM) (10 ng/ml) or left unstimulated. After 72 hours, supernatants and explants were collected. Gene expression of matrix metalloproteinases (MMPs) 1, 3, and 13 were measured by qPCR and levels of MMP-1, MMP-3, MMP-13, ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs), and ADAMTS-5 proteins were measured in supernatants by ELISA. Glycosaminoglycan (GAG) and nitric oxide (NO) levels were measured in supernatants using the dimethylmethylene blue assay and Griess assay, respectively. One-way ANOVA was used for multiple group comparisons.

**Results:** Treatment with IL-1 $\beta$  or TNF- $\alpha$ +OM led to statistically significant increases in gene expression of *MMP1*, *MMP3*, and *MMP13* and increased secretion of GAG, MMP-1, MMP-3, MMP-13, ADAMTS-4, ADAMTS-5, and NO in supernatants compared with unstimulated control. Treatment with LOR decreased both IL-1 $\beta$ -stimulated or TNF- $\alpha$ +OM-stimulated gene expression of *MMP1*, *MMP3*, and *MMP13* and secretion of GAG, MMP-1, MMP-3, MMP-13, ADAMTS-4, ADAMTS-5, and NO in supernatants compared with treatment with DMSO.

**Conclusion:** LOR demonstrated potent inhibition of cartilage catabolic enzyme production in human OA explants compared with controls. These cartilage-protective effects support the development of LOR as a potential disease-modifying treatment for knee OA. Human trials are ongoing.

**Tables:** A) Enzyme protein levels, B) Enzyme gene expression, C) GAG and NO levels  
 Numbers represent normalized versus unstimulated.  $P < 0.05$ , one-way ANOVA

A

Protein levels (Supernatants)	IL-1 $\beta$ stimulation			TNF- $\alpha$ +OM stimulation		
	Mean $\pm$ SEM			Mean $\pm$ SEM		
	DMSO	LOR (10 nM)	LOR (30 nM)	DMSO	LOR (10 nM)	LOR (30 nM)
MMP-1	4.49 (0.2)	<b>1.24</b> <b>(0.03)</b>	<b>1.1</b> <b>(0.02)</b>	8.23 (0.44)	<b>1.01</b> <b>(0.01)</b>	<b>1.0</b> <b>(0.01)</b>
MMP-3	5.97 (0.37)	<b>1.02</b> <b>(0.03)</b>	<b>1.35</b> <b>(0.07)</b>	5.17 (0.32)	<b>1.1</b> <b>(0.02)</b>	<b>1.08</b> <b>(0.04)</b>
MMP-13	14.8 (0.49)	<b>4.57</b> <b>(0.7)</b>	<b>1.93</b> <b>(0.2)</b>	70.78 (3.31)	<b>2.56</b> <b>(0.17)</b>	<b>1.47</b> <b>(0.08)</b>
ADAMTS-4	1.28 (0.02)	1.04 (0.01)	1.09 (0.02)	1.45 (0.03)	1.03 (0.01)	0.91 (0.02)
ADAMTS-5	1.91 (0.1)	<b>1.03</b> <b>(0.03)</b>	<b>1.15</b> <b>(0.03)</b>	2.28 (0.11)	<b>1.24</b> <b>(0.02)</b>	<b>0.87</b> <b>(0.03)</b>

B

Gene expression (Explants)	IL-1 $\beta$ stimulation			TNF- $\alpha$ +OM stimulation		
	Mean $\pm$ SEM			Mean $\pm$ SEM		
	DMSO	LOR (10 nM)	LOR (30 nM)	DMSO	LOR (10 nM)	LOR (30 nM)
<i>MMP1</i>	1.04 (0.01)	0.81 (0.04)	0.71 (0.05)	1.04 (0.01)	<b>0.67</b> <b>(0.03)</b>	<b>0.50</b> <b>(0.03)</b>
<i>MMP3</i>	1.02 (0.01)	0.82 (0.02)	<b>0.56</b> <b>(0.02)</b>	1.03 (0.01)	<b>0.73</b> <b>(0.03)</b>	<b>0.71</b> <b>(0.03)</b>
<i>MMP13</i>	1.05 (0.01)	<b>0.60</b> <b>(0.02)</b>	<b>0.60</b> <b>(0.05)</b>	1.05 (0.01)	<b>0.60</b> <b>(0.03)</b>	<b>0.63</b> <b>(0.03)</b>

C

Supernatants	IL-1 $\beta$ stimulation			TNF- $\alpha$ +OM stimulation		
	Mean $\pm$ SEM			Mean $\pm$ SEM		
	DMSO	LOR (10 nM)	LOR (30 nM)	DMSO	LOR (10 nM)	LOR (30 nM)
GAG	1.35 (0.04)	1.05 (0.03)	<b>0.87</b> <b>(0.02)</b>	2.4 (0.07)	2.02 (0.05)	<b>1.54</b> <b>(0.04)</b>
NO	490.46 (18.69)	<b>0.89</b> <b>(0.05)</b>	<b>0.44</b> <b>(0.03)</b>	144.2 (9.6)	<b>19.79</b> <b>(2.71)</b>	<b>20.09</b> <b>(2.65)</b>